2024, Number 6
<< Back Next >>
Acta Pediatr Mex 2024; 45 (6)
Langerhans histiocytosis. Experience in pediatric age of 7 years in a concentration hospital in Mexico
García GA, Gracián CE, Pérez DMG, Terán CV, Montiel JÁJ, Bertado RNR
Language: Spanish
References: 20
Page: 570-576
PDF size: 207.84 Kb.
ABSTRACT
Background: Langerhans cell histiocytosis (LCH) is a rare disease that affects multiple
organs and/or systems. There are no descriptions of the experience in Mexican
referral hospital
Objective: To describe the clinical characteristics and response to treatment of
patients with LCH.
Materials and Methods: A descriptive, retrospective and longitudinal study was
conducted in a tertiary health care center during 2014 to 2021. Files of pediatric patients
with histopathological diagnosis of LCH were reviewed. Descriptive statistics were used.
Results: Records of 13 patients were evaluated, 61.5% women, mean age 41.23
months (SD 48.29), and 12(92.3%) with multisystem disease. Of the total, 8(61.5%)
required second-line treatment or more. There were 2(14.2%) deaths due to disease
progression and 1(7.14%) due to complications of hematopoietic progenitor cell
transplantation.
Conclusions: There were 13 cases of LCH in children in 7 years, it is a more frequent
disease in children. The mean age of presentation was 41.23 months; predominantly
female. Global mortality was 23%, mean follow-up of 34.15 months. High-risk multisystemic
disease was the most frequent with 61.5%, mortality of 37.5% and mean
follow-up of 32 months.
REFERENCES
Emile JF, Abla O, Fraitag S, Home A, Haroche J, Donadieu J,et al. Revised classification of histiocytoses and neoplasmof the macrophage-dendritic cell lineages. Blood. 2016;127(22): 2672-81. doi: 10.1182/blood-2016-01-690636.
Krooks J, Minkov M, Weatherall AG. Langerhans cell histiocytosisin children: History, classification, pathobiology,clinical manifestations, and prognosis. J Am Acad Dermatol.2018; 78(6): 1035-1044. doi: 10.1016/j.jaad.2017.05.059
Astigarraga I, Garcí a-Obregón S, Pérez-Martínez A, Gutiérrez-Carrasco I, Santa-María V, et al. Histiocitosis de célulasde Langerhans. Avances en la patogenia y práctica clínica.An Pediatr. 2022; 97(2): 130.e1-130.e7. doi: 10.1016/j.anpedi.2022.05.002.
Bello-Lopez LJ, Moraleda-Jiménez JM. Pregrado de Hematología.En: Sociedad Española de Hematología y Hematoterapia. Patología del Sistema Mononuclear Fagocítico.4th ed. España: Luzán; 2017. p. 468-70
Nicholson HS, Egeler RM, Nesbit ME. The epidemiology ofLangerhans cell histiocytosis. Hematol Oncol Clin North Am.1998; 12(2): 379-84. doi: 10.1016/s0889-8588(05)70517-7.
McClain K. Histiocytic disorders: insights into novel biologyand implications for therapy of Langerhans cell histiocytosisand Erdheim-Chester disease. Hematology Am Soc HematolEduc Program. 2020; 2020(1): 395-399. doi: 10.1182/hematology.2020000159
Kobayashi M, Tojo A. Langerhans cell histiocytosis in adults:Advances in pathophysiology and treatment. Cancer Sci.2018; 109(12): 3707-3713. doi: 10.1111/cas.13817.
Hermiston ML. Double trouble for Langerhans cell histiocytosis.Blood. 2021; 137(13): 1705-1706. doi: 10.1182/blood.2020009251.
Jayachandran S, Balaji N. Langerhans Cell Histiocytosis.WJOUD. 2011; 2(1): 57-62. doi: 10.5005/jp-journals-
10015-1055.10. Monsereenusorn C, Rodriguez-Galindo C. Clinical Characteristicsand Treatment of Langerhans Cell Histiocytosis.Hematol Oncol Clin N Am. 2015; 29(5): 853-73. doi:10.1016/j.hoc.2015.06.005.
Dávalos M, Venegas A, Velasco L, Ramírez AG, Durán C.Dermatosis en el área del pañal sin respuesta a tratamientoconvencional. ¿Sospecha de abuso sexual? Acta pediátrMéx. 2023;44(1):23–8. doi: http://dx.doi.org/10.18233/apm44no1pp23-282504
Corcuera CT, Garza R, González L, Velasco L. Histiocitosisde células de Langerhans senescentes. Informe de caso.Acta pediátr Méx. 2016;37(2):94. doi: http://dx.doi.org/10.18233/apm37no2pp94-101
Morán E, Durán C, Orozco L, Palacios C, Sáez M, García MT.Histiocitosis de células de Langerhans: nuevos conceptosmoleculares y clínicos. DQMQ. 2017; 16(1): 36-42.
Lian C, Lu Y, Shen S. Langerhans cell histiocytosis in adults: acase report and review of the literature. Oncotarget. 2016;7(14): 18678-83. doi: 10.18632/oncotarget.7892.
Hashimoto K, Nishimura S, Sakata N, Inoue M, Sawada A,Akagi M. Treatment Outcomes of Langerhans Cell Histiocytosis:A Retrospective Study. Medicina (Kaunas). 2021;57(4): 356. doi: 10.3390/medicina57040356
Widodo I, Sahara N, Dwianingsih EK, Ferronika P. Caseseries of cutaneous Langerhans cell histiocytosis in Indonesianchildren; The clinicopathological spectrum. DermatolReports. 2020; 12(2): 8777. doi: 10.4081/dr.2020.8777.
Ong AA, Rosi-Schumacher M, Pizzuto M. Langerhans CellHistiocytosis of the Skull. Ear Nose Throat J. 2021; 100(4):219-221. doi: 10.1177/0145561319869605.
Barrios K, Patiño O, Muñoz N, Moneriz C. Congenital Langerhanscell histiocytosis. Biomedica. 2020; 40(3): 464-471.doi: 10.7705/biomedica.5150.
McClain KL, Allen CE. Williams Hematology. En: KaushanskyK, Lichtman MA, Prchal JT, Levi MM, Press OW, Burns LJ, CaligiuriM, editor. Inflammatory and Malignant Histiocytosis.9th ed. New York: McGraw-Hill Education; 2015. p. 1-40.
Abla O, Weitzman S. Treatment of Langerhans cell histiocytosis:role of BRAF/MAPK inhibition. Hematology Am SocHematol Educ Program. 2015; 2015: 565-70. doi: 10.1182/asheducation-2015.1.565